In this issue:
- Atezolizumab + bevacizumab in unresectable HCC (IMbrave150)
- TACE + durvalumab ± bevacizumab in unresectable HCC (EMERALD-1)
- The STRIDE regimen in unresectable HCC (HIMALAYA)
- Immune-related adverse events with atezolizumab + bevacizumab
- Atezolizumab + bevacizumab in patients at high risk for recurrence (IMbrave050)
- Non-contrast abbreviated MRI vs ultrasound for HCC surveillance
- Lenvatinib + TACE as first-line treatment for advanced HCC (LAUNCH)
- Bleeding and thromboembolic events with atezolizumab/ bevacizumab vs lenvatinib
- Treatment of portal hypertension in patients with HCC in the era of Baveno VII
Please login below to download this issue (PDF)